Clinical Trials
54
Active:1
Completed:10
Trial Phases
5 Phases
Early Phase 1:4
Phase 1:8
Phase 2:7
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
Not Applicable
17 (40.5%)Phase 1
8 (19.0%)Phase 2
7 (16.7%)Phase 4
6 (14.3%)Early Phase 1
4 (9.5%)Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Not Applicable
Recruiting
- Conditions
- Angioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma Refractory
- Interventions
- Drug: tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Target Recruit Count
- 40
- Registration Number
- NCT07058103
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Not Applicable
Not yet recruiting
- Conditions
- Multiple Myeloma (MM)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Chimeric Antigen Receptor T-cell
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-07-02
- Target Recruit Count
- 20
- Registration Number
- NCT07034755
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome
Not Applicable
Not yet recruiting
- Conditions
- Budd-Chiari Syndrome
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 260
- Registration Number
- NCT06960473
- Locations
- 🇨🇳
Department of Interventional Radiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
Phase 2
Not yet recruiting
- Conditions
- HCC - Hepatocellular CarcinomaAdjuvant Treatment
- Interventions
- Drug: Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 60
- Registration Number
- NCT06958484
Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes
Active, not recruiting
- Conditions
- HFpEFHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Target Recruit Count
- 500
- Registration Number
- NCT06916611
- Locations
- 🇨🇳
the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found